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BACKGROUND: The prognosis of patients with cancer- venous thromboembolism (VTE) is not well known because of a lack of 
registry data. Moreover, there is also no knowledge on how specific types are related to prognosis. We sought to evaluate 
the clinical characteristics and outcomes of patients with cancer- associated VTE, compared with a matched cohort without 
cancer using real- world registry data of VTE.
METHODS AND RESULTS: This study was based on the Diagnosis Procedure Combination database in the JROAD- DPC 
(Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination). Of 5 106 151 total pa-
tients included in JROAD- DPC, we identified 49 580 patients who were first hospitalized with VTE from April 2012 to March 
2017. Propensity score was estimated with a logistic regression model, with cancer as the dependent variable and 18 clinically 
relevant covariates. After propensity matching, there were 25 148 patients with VTE with or without cancer. On propensity 
score- matched analysis with 25  148 patients with VTE, patients with cancer had higher total in- hospital mortality within 
7 days (1.3% versus 1.1%, odds ratio [OR], 1.66; 95% CI, 1.31– 2.11; P<0.0001), 14 days (2.5% versus 1.5%, OR, 2.07; 95% CI, 
1.72– 2.49; P<0.0001), and 30 days (4.8% versus 2.0%, OR, 2.85; 95% CI, 2.45– 3.31; P<0.0001). On analysis for each type of 
cancer, in- hospital mortality in 11 types of cancer was significantly high, especially pancreas (OR, 12.96; 95% CI, 6.41– 26.20), 
biliary tract (OR, 8.67; 95% CI, 3.00– 25.03), and liver (OR, 7.31; 95% CI, 3.05– 17.50).
CONCLUSIONS: Patients with cancer had a higher in- hospital acute mortality for VTE than those without cancer, especially in 
pancreatic, biliary tract, and liver cancers.
Key Words: cardio- oncology ■ mortality ■ venous thromboembolism
Venous thromboembolism (VTE), including pulmo-nary embolism (PE) and deep vein thrombosis, is a major cause of death in patients with cancer.1 
It is also well known that cancer is a strong risk factor 
for the development of VTE. Patients with cancer are 
reported to have a 4 to 8 times higher incidence com-
pared with patients without cancer.2– 4 In addition, sev-
eral metabolic factors, including a trend toward a diet 
rich in meat and fat, decline in physical activity, and 
increasing incidence of obesity, continue to increase 
the risk of developing VTE.5 Thus, an optimal manage-
ment strategy for patients with VTE and cancer is a 
major need in daily clinical practice.
To understand current issues and improve patient 
care and prognosis, data on current real- world clinical 
outcomes in patients with cancer- associated VTE are 
important. Despite several guideline recommendations 
about VTE, there is still a lack of robust data on these 
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patients for their prognosis.6 Malignancies of the brain, 
stomach, pancreas, lungs, uterus, and ovaries were 
well known to be associated with high incidence rate 
of VTE.7,8 Not only is VTE considered an independent 
negative prognostic factor, but the resulting reduction 
in quality of life can delay cancer treatment, lead to 
more frequent and prolonged hospitalizations, and re-
sult in higher treatment costs. Some previous reports 
for prognosis have focused on the presence of can-
cers, but few studies have examined the prognosis on 
the individual cancer types during hospitalization.9,10 
Therefore, we sought to evaluate the clinical character-
istics and outcomes of patients with cancer- associated 
VTE compared with the matched cohort without can-
cer using a real- world registry data of VTE. Our hy-
pothesis was that cancer type is associated with an 
increased short- term risk of death (mortality within 7, 
14, or 30 days) during hospitalizations in patients with 
VTE.
METHODS
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject con-
fidentiality protocols may be sent to the Japanese 
Circulation Society via e-mail ( j-circdb@ml.ncvc.
go.jp).
Study Population
The study population was composed of hospital-
ized patients from April 2012 to March 2017 in the 
JROAD- DPC (Japanese Registry of All Cardiac and 
Vascular Diseases and the Diagnosis Procedure 
Combination) database. JROAD- DPC is a nation-
wide registry, a medical database with information 
on admission and discharge for cardiovascular dis-
eases, clinical examinations and treatment status, 
patient status, and hospital overview. The JROAD- 
DPC database integrates the information composed 
by JROAD- DPC data, with analysis data sets cover-
ing 5.1 million cases in 1022 hospitals between April 
2012 and March 2017. The identification of VTE and 
cancer was based on the International Classification 
of Diseases, Tenth Revision (ICD- 10) diagnosis codes 
related to PE (I26.0, I26.9); deep vein thrombosis 
(I80.0, I80.1, I80.2, I80.3, I80.9, I82.2, I82.3, I82.9, 
O22.2, O22.3, O22.9, O87.0, O87.1, O87.9); cancer 
of esophagus (C15), stomach (C16), colon (C18– 20), 
liver (C22), biliary tract (C23– 24), pancreas (C25), 
lung (C34), breast (C50), cervix (C53), uterine body 
(C54), ovary (C56), prostate (C61), kidney and urinary 
tract (C64– 66, 68), and bladder (C67); and leuke-
mia (C91– 95). Patient age and sex, main diagnosis, 
comorbidity at admission, length of hospitalization, 
and treatment content were extracted from the data-
base. We included 54 976 patients hospitalized with 
VTE (Figure 1). Diagnosis of VTE was defined as the 
main diagnosis, admission- precipitating diagnosis, 
CLINICAL PERSPECTIVE
What Is New?
• On propensity matched analysis with 25  148 
patients with venous thromboembolism, pa-
tients with cancer had higher total in- hospital 
mortality within 14 days and within 30 days.
• On analysis for each type of cancer, in- hospital 
mortality in 11 types of cancer was significantly 
high, especially pancreas (odds ratio [OR], 
13.48; 95% CI, 6.74– 26.96), biliary tract (OR, 
9.12; 95% CI, 3.17– 26.24), and liver (OR, 7.96; 
95% CI, 3.20– 19.82).
What Are the Clinical Implications?
• The knowledge from a high- risk cohort of venous 
thromboembolism with specific cancers may 
be useful for the management of patient care 
and prevention of venous thromboembolism.
Nonstandard Abbreviations and Acronyms
PS propensity score
Figure 1. Flowchart of this study.
JROAD- DPC indicates The Japanese Registry of All Cardiac and 
Vascular Diseases and the Diagnosis Procedure Combination; 
and VTE, venous thromboembolism.
50,696 patients first hospitalized for VTE
(Calculation of cancer type proportion)
Excluded (n=1,116)
・Age < 20 years (n=219)
・Death in 24 hour (n=897)
Evaluation for propensity score (n=49,580)
Cancer (n=12,574) ： Non Cancer (n=37,006)
JROAD-DPC database (from 1,022 hospitals)
between April 2012 and March 2017
(n=5,106,151)
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or most resource- consuming diagnosis. Medical 
resources were determined by the cost of exami-
nations and treatments during hospitalization. Most 
resource- consuming diagnosis was defined by the 
doctor’s discretion based on medical resources and 
the main diagnosis disease. After excluding patients 
with unknown age or patients who were readmitted 
(readmission for VTE was defined as the first read-
mission after discharge from the initial hospitaliza-
tion), 12 685 patients (25.0%) of 50 696 patients had 
cancer. To confirm that the stratification of cancer 
types did not deviate from the national statistics and 
to identify which cancer types were more frequently 
hospitalized for VTE in Japan, we calculated cancer 
type proportion of 12 685 patients with cancer and 
compared it with national statistics. Subsequently, we 
excluded 219 patients aged <20 years and 897 who 
died within 24  hours after admission. Patients who 
died within 24 hours after admission were excluded 
because their medical histories were not properly 
interviewed, and JROAD- DPC data may have been 
omitted. As a result, 12  574 patients with cancer 
and 37  006 patients without cancer were included 
to assess hospital mortality. The Institutional Review 
Board of the Tokushima University Hospital approved 
the study protocol (no. 3503) and waived the require-
ment for individual informed consent because infor-
mation specific to individuals is not included.
Clinical Outcomes
The main outcome was in- hospital mortality death ≤7, 
14, and 30 days after admission, because acute and 
subacute mortality are mainly related to VTE in this 
cohort. Total number of deaths after admission was 
assessed as secondary outcomes. Patients were cen-
sored upon discharge and were not followed beyond 
that point.
Sample Matching
Propensity score (PS) matching was used to reduce 
confounding effects related to differences in patient 
background. After matching, 12 574 patients each in 
the cancer and noncancer groups were included in the 
final analysis. Concordance index was 0.64 and the 
consistency of PS densities was matched after match-
ing (Figure S1). The balance of each covariate before 
and after the matching between the 2 groups was 
evaluated by standardized differences. Absolute value 
of standardized differences <10% was considered to 
be a relatively small imbalance.
Patient and Public Involvement Statement
Neither patients nor the public were involved in the 
design, conduct, reporting, or dissemination of our 
research.
Statistical Analysis
The Shapiro- Wilk test was used to assess the normal 
distribution of continuous data. Continuous variables 
are expressed as mean±SD for parameters with nor-
mal distribution, as median (interquartile range) for 
parameters with skewed distribution, and categorical 
variables as proportion (%). PS was estimated with a 
logistic regression model, with cancer as the depend-
ent variable and the following 18 clinically relevant 
covariates: age, sex, hypertension, diabetes mellitus, 
dyslipidemia, congestive heart failure, myocardial in-
farction, peripheral vascular disease, cerebrovascu-
lar disease, chronic pulmonary disease, rheumatic 
disease, moderate- severe chronic kidney disease, 
moderate- severe liver failure, PE, dementia, and use 
of intra- aortic balloon pumping, percutaneous cardio-
pulmonary support, and catecholamine for treatment. 
These covariates were chosen for their potential as-
sociation with reference to risk factor of thromboem-
bolism and mortality.11– 13 Matching was performed with 
greedy- matching algorithm (ratio=1:1 without replace-
ment), with a caliper of width 0.2 SDs of the logit of 
the estimated PS. After matching, we estimated the 
odds ratio (OR) and 95% CI with cancer for in- hospital 
mortality (total, within 7 days, 14 days, and 30 days) 
by matched logistic regression analysis adjusted for 
hospitalization days. To confirm that the results were 
similar, we used inverse probability treatment weight-
ing with a logistic regression model adjusted for hos-
pitalization days in the full sample before matching. 
We assigned patients with cancer a weight of 1÷PS 
and patients without cancer a weight of 1÷(1−PS). We 
also analyzed subgroups by type of cancer in the PS- 
matched cohort. The OR for each type of cancer was 
calculated using matched patients without cancer as 
controls. In- hospital mortality was assessed using 
Kaplan- Meier method and compared between pa-
tients with and without cancer using log- rank test. All 
statistical tests were 2- sided and P values <0.05 were 
considered statistically significant. Statistical analysis 
was performed using SAS version 9.4 and JMP 14.0 
(SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
In the group before PS matching (n=49 580), a total of 
40.3% (n=19 995) of this group were male, with a me-
dian age of 72  years (range: 60– 81  years) and 51.2% 
(n=25 385) had PE. In patients without cancer, there was 
a significantly larger prevalence of hypertension, dyslipi-
demia, cerebrovascular disease, congestive heart fail-
ure, rheumatic diseases, and dementia than in patients 
with cancer. The distribution of other comorbidities was 
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of each type of cancer from patients before second ex-
clusion (Figure 2). Gastric, colon, and lung cancers ac-
counted for more than 40% of the total cancer type, 
which was equivalent to the national statistics. On the 
other hand, the proportion of cancer of cervix, uterine 
body, and ovary in this study were 3 to 5 times higher 
than the national statistics. After PS matching, 24 432 
patients were excluded and 25  148 patients were in-
cluded in the analysis. In the matched cohort, there were 
no differences between groups of patients with cancer 
versus noncancer for age, sex, comorbidities, PE, intra- 
aortic balloon pumping, percutaneous cardiopulmonary 
support, and catecholamine treatment (Table 1). Median 
hospitalization length was slightly longer in the group 
with cancer than noncancer (16 days versus 14 days, 
standard difference=19.5). The median length of hospi-
talization was relatively long in this cohort because we 
selected patients with poorer conditions, not those in 
outpatient care.
Outcomes
Patients with VTE and cancer had significantly higher in- 
hospital mortality at 7, 14, and 30 days postadmission 
compared with those without cancer (Table 2). The OR 
after matching was higher than before matching in all pe-
riods. Because all patients with cancer were matched, 
the change in OR depended on the change in mortality 
of patients without cancer after matching. Kaplan– Meier 
curves of in- hospital mortality after matching were shown 
in Figure 3. In this analysis, patients with cancer had a 
significantly higher mortality than those without cancer 
(P<0.001). In inverse probability treatment weighting with 
logistic regression model, in- hospital mortality within 
7 days (OR, 1.29; 95% CI, 1.15– 1.45), within 14 days (OR, 
1.71; 95% CI, 1.57– 1.87), and within 30 days (OR, 2.22; 
95% CI, 2.07– 2.38) were significantly higher in patients 
with cancer (Table 2).
Prognostic Impact by Cancer Types
For hospitalization mortality of each cancer type, forest 
plots of ORs are shown in Figure 4. Patients with stom-
ach, colon, liver, biliary tract, pancreas, lung, breast, 
cervix, uterine body, ovary, or bladder cancers had 
significantly higher in- hospital mortality than matched 
patients without cancer. Mortality in pancreatic can-
cer was especially high, followed by biliary tract and 
liver cancer. Patients with esophageal cancer, prostate 
cancer, kidney and urinary tract cancer, or leukemia 
had no significant difference in in- hospital mortality 
compared with matched patients without cancer.
DISCUSSION
The main findings of the study were (1) among patients 
hospitalized with cancer and VTE, gastric, colon, and 
lung cancers accounted for more than 40% of the 
total cancer type, which was equivalent to the national 
Figure 2. Proportion of cancer type of first hospitalized patients with VTE and comparison with national statistics.
Data are presented as [each cancer proportion of national statistics (%) and this study (%)]. VTE indicates venous thromboembolism.
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statistics; (2) patients with VTE and cancer had signifi-
cantly higher acute hospital mortality (within 7, 14, and 
30  days of hospitalization); and (3) patients with pan-
creatic cancer had especially high in- hospital mortality, 
followed by those with biliary tract and liver cancer. To 
the best of our knowledge, this is the first report assess-
ing the relationship between cancer and acute mortality 
during hospitalization in a large- scale cohort of VTE.
Impact of Cancer on VTE
After matching, mortality within 7, 14, and 30 days of 
hospitalization in patients with VTE and cancer were 
higher than patients without cancer. As shown in 
Table  2, patients with VTE who did not have cancer 
before PS matching had a higher mortality rate than 
after matching. Providers should not underestimate 
the mortality associated with VTE in patients without 
cancer.
Patients with cancer are more likely to have acute 
thrombotic events because of changes in the coagu-
lation and fibrinolytic systems.14 The cause is thought 
to be that tissue factor, mucin, and cytokines derived 
from cancer cells activate the coagulation system 
and contribute to the development of thrombosis.15,16 
Because of these mechanisms, patients with cancer 
Table 1. Baseline Characteristics Before and After Propensity Score Matching
Nonmatching Matching
All Cancer Noncancer Std. diff Cancer Noncancer Std. diff
(n=49 580) (n=12 574) (n=37 006) (n=12 574) (n=12 574)
Age, y 72 (60– 81) 70 (61– 79) 73 (59– 81) −2.0 70 (61– 79) 70 (60– 79) 0.7
Male sex, % 40.3 42.4 39.6 5.6 42.4 42.4 <0.1
Pulmonary embolism, % 51.2 51.3 51.2 0.2 51.3 51.7 −0.8
Comorbidities, %
Hypertension 28.9 23.1 30.8 −17.5 23.1 23.2 −0.1
Diabetes mellitus 13.5 13.3 13.5 −0.8 13.3 13.3 −0.2
Dyslipidemia 14.0 9.0 15.7 −20.4 9.0 9.0 <0.1
Stroke 5.8 4.2 6.4 −9.6 4.2 4.1 0.6
Congestive heart 
failure
15.3 11.2 16.7 −16.0 11.2 11.2 <0.1
Myocardial infarction 1.4 0.9 1.6 −6.8 0.9 0.9 0.2
Peripheral vascular 
disease
2.7 1.6 3.1 −9.7 1.6 1.5 0.6
Chronic kidney 
disease
2.9 2.1 3.2 −6.4 2.1 2.2 −0.6
Liver failure 0.1 0.2 0.1 2.0 0.2 0.2 1.2
Chronic obstructive 
pulmonary disease
4.7 4.7 4.7 0.3 4.7 4.6 0.6
Rheumatic diseases 3.2 1.9 3.7 −10.8 1.9 1.9 0.1
Dementia 4.7 2.6 5.4 −14.7 2.6 2.5 0.1
Treatment, %
Warfarin 54.9 55.1 54.9 0.6 55.1 55.1 0.1
Direct oral 
anticoagulants
32.1 33.0 31.8 2.7 33.0 32.7 0.7
Heparin 80.1 82.1 79.4 6.9 82.1 79.4 6.9
Catecholamines 5.7 5.2 5.9 −3.2 5.2 4.7 2.0
Intra- aortic balloon 
pumping




1.3 0.8 1.5 −7.0 0.8 0.8 −0.6
Inferior vena cava filter 27.3 30.3 26.3 9.0 30.3 26.8 7.7
Chemotherapy 3.3 13.0 NA NA 13.0 NA NA
Hospitalization (d) 16 (10– 24) 16 (10– 26) 15 (9– 22) 14.0 16 (10– 26) 14 (9– 21) 19.5
Data are presented as percentage of patients or median (interquartile range). A standardized difference of <10% suggests adequate balance. NA indicates 
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have 4 to 8 times higher risk of VTE incidence than 
patients without cancer.2– 4 Therefore, thromboem-
bolism is the second leading cause of death in out-
patient cancer cases.1 Based on our results, VTE had 
a high mortality rate at short term. Early detection 
and treatment of deep vein thrombosis in patients 
with cancer may improve patient prognosis.
Cancer and Bleeding Risk
Patients with cancer often develop cachexia and weight 
loss.17 In addition, chemotherapy, sepsis, tumor lysis 
syndrome, and contrast agent nephropathy can cause 
acute renal failure in patients with cancer.18 For treatment 
of VTE in cancer cases, low molecular weight heparin 
and direct oral anticoagulants are recommended by the 
European Society of Cardiology and American Society 
of Clinical Oncology19,20, but these drugs may be dif-
ficult to control owing to low body weight and renal fail-
ure and may increase the risk of bleeding. In addition, 
chemotherapy occasionally causes anemia and throm-
bocytopenia.21,22 Therefore, it is also reported that an-
ticoagulant therapy for cancer- related VTE had 6 times 
higher risk of bleeding than noncancer VTE. It is nec-
essary to consider the bleeding risk and prognosis for 
each case.23
Differences of Incidence and Prognosis 
by Cancer Types
Compared with national statistics on cancer incidence, 
hospitalized patients with VTE and cancer tended to 
have a higher percentage of gynecological malignan-
cies. Gynecological cancers are thought to cause 
thromboembolic events because of surgery (pelvic vis-
ceral resection, inguinal lymphadenectomy) and venous 
congestion for tumors or enlarged lymph nodes.24 Also, 
gynecological cancer has a 5- year survival rate of more 
than 60% to 80%.25 Thus, our VTE cohort may also in-
clude many patients with high VTE risk and high survival 
rate from cancer (eg, gynecological cancers).
From our data, the ORs of mortality for pancreatic, 
biliary tract, and liver cancers were higher than the 
other cancers. We consider the following as causes. 
First, liver and biliary tract cancers often cause he-
patic dysfunction. Anticoagulants for VTE, warfarin 
and several direct oral anticoagulants, are metabolized 
in the liver. Hepatic dysfunction may lead to unsta-
ble anticoagulant effects and affect the prognosis.26 
Patients with liver cancer may have underlying cirrho-
sis. Esophageal varices increase the risk of bleeding 
from anticoagulation therapy.27 After patients develop 
VTE 30- day mortality rates are twice as high for pa-
tients with cirrhosis.28 Second, pancreatic cancer and 
ovarian cancer are mucin- producing tumors. Mucin 
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Clinical Implication
Although cancer is associated with a high incidence 
of VTE and there are many guidelines/recommen-
dations about VTE, the prognosis of patients with 
cancer- VTE is not well known because of a lack of 
registry data. Moreover, there is also no knowledge 
on which type of cancer is related to worse progno-
sis. According to our results, patients with VTE and 
cancer had a high acute hospital mortality, and pa-
tients with VTE and pancreatic, biliary tract, or liver 
cancer seemed to be at the highest risk of in- hospital 
mortality compared with matched patients with VTE 
without cancer. It has been reported that low molec-
ular weight heparin is effective in preventing thrombi 
formation in patients at high risk of VTE.31,32 Recently, 
some studies have focused on the effectiveness of 
direct oral anticoagulants use in these patients,33 
perhaps providing us with another means of treat-
ment. We believe that knowledge from a high- risk 
cohort of VTE with specific cancers may be useful 
for the management of patient care.
Limitations
The study based on ICD codes has several limitations. 
First, we analyzed only hospitalized patients with VTE 
in the database, which may lead to a selection bias. 
Even if the patients had developed VTE during cancer 
hospitalization (patients had anticancer drugs or sur-
gery), these patients were not included as the most 
resource- consuming diagnosis in such cases would 
be registered as “cancer.” When the most resource- 
consuming diagnosis is cancer, cancer itself may 
have a strong impact on mortality. Thus, we did not 
pick up these patients in this analysis. Second, the 
database has no information on echocardiography, 
laboratory data (D- dimer), or radiation therapy to as-
sess the prognosis of VTE. Third, the accuracy of the 
diagnosis is not perfect, because these are less vali-
dated in the JROAD- DPC database compared with 
planned prospective studies. However, the original 
JROAD- DPC data set has been validated34 and we 
believed that consistency is relatively high for the data 
set. Fourth, it is unknown whether patients diagnosed 
with cancer had already finished cancer treatment. 
Fifth, PS matching reports the potential differences 
between groups but is never perfect. Despite the ap-
plication of PS matching to the comparator group 
of patients, this nonrandomized observational study 
could still be subject to hidden biases related to pa-
tient selection, because of unknown unadjusted dif-
ferences. To overcome this issue, we used circulatory 
assist devices and catecholamine medication as 
markers of VTE severity. All- cause mortality was used 
Figure 3. Kaplan- Meier curves of in- hospital mortality and hospitalization days compared 
between patients with and without cancer.
 
Cancer 12,574 11,188 7,621 4,554 2,792
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as the primary end point in our patient population. We 
found a high prevalence of PE in patients who died 
within 7 days (92.9%), 14 days (89.7%), and 30 days 
(84.0%) in this study. Thus, the most likely cause of 
acute death in our patient population is PE, although 
deaths from other diseases were unable to be com-
pletely excluded.
Although discerning how the presence of cancer is 
associated with risk of sudden death, major adverse 
cardiac events, major bleeding, or cancer death would 
be of important interest, determining the definitive cause 
of death by death certificates can be difficult in such a 
very high- risk population and can pose a source of bias. 
The patients in this study are mostly Japanese. Results 
may differ because of racial/ethnic differences com-
pared with other countries. This study included only pa-
tients hospitalized for VTE because we focused on the 
high- risk group to clarify the relationship between VTE 
and cancer. Our results are unable to be applied to the 
outcome of outpatients. Considering these limitations, a 
prospective study involving a large number of patients 
with VTE should also be performed in other countries.
CONCLUSIONS
Patients with cancer had a higher acute mortality 
during hospitalization for VTE than patients without 
cancer, especially in pancreatic, biliary tract, and liver 
cancers.
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Figure 4. Odds ratio (OR) of in- hospital mortality in patients with each cancer compared with matched patients without 
cancer.
Dots and lines indicate OR and 95% CI, respectively.
Higher riskLower risk n death OR lower upper P value
12574 921 3.08 2.70 3.52 <.0001
192 14 2.32 0.86 6.22 0.0836
1742 141 3.54 2.47 5.07 <.0001
2309 122 2.68 1.89 3.79 <.0001
334 40 7.31 3.05 17.50 <.0001
232 32 8.67 3.00 25.03 <.0001
558 101 12.96 6.41 26.20 <.0001
1634 176 4.49 3.18 6.33 <.0001
617 36 2.31 1.27 4.21 0.0062
466 32 3.59 1.69 7.65 0.0009
674 35 2.00 1.10 3.61 0.0222
807 57 5.16 2.68 9.94 <.0001
874 34 1.06 0.65 1.75 0.8138
350 23 1.90 0.92 3.91 0.0807
407 40 3.01 1.57 5.75 0.0009
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Figure S1. a: Receiver operating characteristic curve and concordance index. b: 
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